Botswana study reveals hidden link between HIV, EBV, and lymphoma
NCT ID NCT06444152
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examines stored lymph node samples from 100 people in Botswana who had lymphoma between 2012 and 2017. Researchers want to see how often Epstein-Barr virus (EBV) is found in these samples, and whether HIV infection makes a difference. The goal is to better understand the role of EBV in lymphomas in this region.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
100 people
The number who actually took part.
- Started
-
Aug 2023
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Formalin fixed paraffin embedded tissue (FFPE) of lymph node excision biopsy samples from the patient with a diagnosis of lymphoma
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * All available lymph node biopsy samples with a diagnosis of lymphoma and complete data of HIV status, HIV viral load and CD4 counts and ART history will be retrieved from IPMS. Exclusion Criteria: * Samples with incomplete data
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Lymph node excision biopsy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Botswana
Gaborone, 267, Botswana
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mitochondria-Targeting drug gamitrinib tested for first time in humans
- Reprogrammed immune cells target CD30-Positive lymphoma in early trial
- Can an experimental pill boost cancer immunotherapy? early trial puts HG146 to the test
- Double-Drug attack on Hard-to-Treat lymphomas
- Chemotherapy plus immunotherapy tested against rare EBV-Driven immune storm
- Can a calming drug make cord blood transplants safer?